Merger trend prompts new advocacy group

Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Kerenida is currently approved to slow the progression of chronic kidney disease associated with type 2 diabetes.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

A forecast for this year by Dan Parsons, chief experience officer of Thoughtful AI.

Fianlimab plus Libtayo demonstrated persistent and significant clinical activity in patients with advanced melanoma.